Light Mode
$0.6602 ↑ +0.0202 (+3.16%) Trading Up from the previous close of $0.6400
-1.60 (-71.43%) / 6M
Momentum, market sentiment, and recent alerts
LTRN reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -83.9%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.